Flubromazolam
1Provenance card
the boundary, as counts
Sources
3532 with DOI
2 strong · 26 moderate · 7 weak
Compilations
12026-04-26T00:34:07.285Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
32last ruled 2026-06-04
1 awaiting a ruling
Issued documents
42026-10-19T20:32:02.585Z
notice · info card · emergency
Searches
213 with no results
queries and counts on the build
Claims checked
9576 supported
76 supported · 19 not
Correspondence
0received
consent field ships in Phase 4
Edges
290
derivations recorded for this entity
Complete over 35 sources, 1 compilation, and 32 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/flubromazolam/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-10-02srcDetectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
- 2026-10-02srcIn vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples
- 2026-10-02srcFlubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine
- 2026-10-02srcDesigner benzodiazepines: A new challenge
- 2026-10-02srcCharacterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites
- 2026-10-02srcAn outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program
- 2026-10-02srcPost mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and Wales
- 2026-10-02srcThe use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines
- 2026-10-02srcDesigner benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam
- 2026-10-02srcDeveloping an animal model to detect drug-drug interactions impacting drug-induced respiratory depression
- 2026-10-02srcStructural and dynamic mechanisms of GABAA receptor modulators with opposing activities
- 2026-10-02srcFlubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam
- 2026-10-02srcThe Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
- 2026-10-02srcFast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
- 2026-10-02srcIncreasing prevalence of designer benzodiazepines in impaired driving: A 5-year analysis from 2017 to 2021
- 2026-10-02srcSuspected North Carolina counterfeit pill-involved deaths, 2020-2022
- 2026-10-02srcDeaths involving novel benzodiazepines in Victoria, Australia from 2018 to 2022
- 2026-10-02srcMultiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700
- 2026-10-02srcThe surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco
- 2026-10-02srcAdverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses.
- 2026-10-02srcThe Pharmacology and Toxicology of the 'Holy Trinity'
- 2026-10-02srcCould Flumazenil Be Used Pre-hospital by Intramuscular Injection for Coma due to Mixed Drug Overdose Not Responding to Naloxone?: A Systematic Review
- 2026-10-02srcThe Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction - A Narrative Review
- 2026-10-02srcSuccessful symptom-based management of active withdrawal from multiple illicit benzodiazepines
- 2026-10-02srcBenzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
- 2026-10-02srcTrends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020
- 2026-10-02src'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
- 2026-10-02srcRecent findings and advancements in the detection of designer benzodiazepines: a brief review
- 2026-10-02srcFlubromazolam – A new life-threatening designer benzodiazepine
- 2026-10-02srcBenzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches.
- 2026-10-02srcNovel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
- 2026-10-02srcDesigner Benzodiazepines: A Review of Toxicology and Public Health Risks
- 2026-10-02srcSchedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
- 2026-10-02srcSchedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
- 2026-10-02srcCritical Review Report: FLUBROMAZOLAM
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-07-03proposaldependence · taper
- 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-04-26revisionRevision 1
- 2026-04-26absenceSearched ClinicalTrials.gov for "flubromazolam" — no results
- 2026-04-26absenceSearched ClinicalTrials.gov for "flubromazolam" — no results
- 2026-04-26absenceSearched PubMed for "flubromazolam GABA receptor binding affinity Ki" — no results
- 2026-04-26genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-04-26rungeneration run
The same entries, as forms: six forms.